Investment Gems

Quick one before the weekend. I want this on the record while it’s still early, because I think the rotation just told us where it’s going and by the time it’s obvious we’ll be paying up for it.

The read, up top so you can argue with it: the “sell AI” trade that started in early summer has quietly grown a positive side, and that side is healthcare. I’m now treating healthcare, biotech specifically, as the emerging leadership until the tape says otherwise, and I’ve started scaling in. Here’s the work behind it, because I don’t want you taking this on my word.

It started as an accident. Our screen, the one built to flag momentum before it’s too obvious, came back last week about 80% healthcare on the confirmed-breakout leg. 41 names that just printed volume-backed 52-week highs out of multi-year bases, and 27 of them are biotech, another 6 device and diagnostics. I did not point the screen there. It went on its own, which is the only kind of signal I actually trust.

What makes me size it rather than note it is that the same thing prints at three levels at once. Bottom: the wreckage names, FATE, CRNX, LGND, EXEL, PTCT and a long tail, all breaking out together. Middle: XLV is the leader on the month, up 6.3%, and it’s the closest of any sector to its own 52-week high, down just 2%. Top: LLY, up 27.5% over three months, out in front of the entire mega-cap complex. Small, sector, and general moving in the same direction in the same week is a re-rating. One of the three alone is noise.

Now the regime, because this is where I could be fooling myself and it’s the part I checked hardest. This is a risk-on rotation, not a fear bid. Gold is down 5.7% on the month, silver down 14, precious metals coming apart, which is disinflation and rising real yields, not a hedge grab. Vol is on the floor, VIXY down 30% over three months. Credit is fine and, tellingly, high yield is outperforming investment grade, so what pressure exists is a rates story, not a solvency one. And breadth is broadening, not narrowing, IWM up 3.3% on the month. So healthcare is not catching a defensive panic bid. It’s catching real rotation flow in a calm, disinflationary tape.

The funding side confirms it. The money is leaving the crowded trade. XLK is down 1.5% on the month despite being up 28% over three, so it’s distribution, not collapse. The tech generals are the ones rolling: MSFT down 6.9%, NVDA down 2.2%, AVGO down 2, TSLA down 3.7%, bitcoin soft, QQQ flat. Capital is walking out of the year’s winners and into healthcare, financials, and industrials. Zero-sum in the short run, and healthcare is where a chunk of it is landing.

How I’m actually playing it, two sleeves. The first is the base sleeve, the deep-drawdown biotech that’s turning but not yet confirmed, sized small and wide because the failure rate there is brutal, these are options on a re-rating more than positions. The second is the confirmation sleeve, the Screen B names that already broke out on volume, sized up because the market has voted and I’m paying for less uncertainty. I’m funding both partly out of trimmed semis, which is convenient because I wanted that risk down anyway. XLV itself is the clean expression if you don’t want single-name clinical risk, and honestly for the fund’s beta that may be the right first move before we get cute with names.

The candid part, because you’d catch me on it anyway. I’m a semis and AI guy by temperament, I’ve under-owned healthcare for two years, so this is exactly the setup where I should distrust my own read, either I’m slow to admit my trade is done or I’m overcorrecting into a fresh story. Weigh that.

What takes me out, and it’s specific. Biotech is long duration, same as the tech we’re rotating out of, same disease different room. Right now yields are only drifting up, so the beaten-down-plus-defensive combo wins and the rotation favors us. A sustained spike in the ten-year is the one thing that hits biotech the way it’s already hitting the AI names, and in that world our newest leader is the first thing that breaks. So I’m keeping the base sleeve small until I see how yields behave into next week.

Net, where I land: I think this is durable and I’m building, but I’m building at a pace that survives being wrong. The single thing I’m watching is whether XLV holds leadership while the ten-year rises. If those two start to disagree, healthcare rolls before my P&L tells me, and that’s the tell I want us all watching, not the biotech headlines.